The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques.

[1]  A. Coats,et al.  Ethical authorship and publishing. , 2009, International journal of cardiology.

[2]  Yong Chen,et al.  The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.

[3]  E. Maltezos,et al.  High-Sensitivity CRP Is Correlated With Neurologic Symptoms and Plaque Instability in Patients With Severe Stenosis of the Carotid Bifurcation , 2008, Vascular and endovascular surgery.

[4]  D. Celermajer,et al.  Atherosclerosis-underlying inflammatory mechanisms and clinical implications. , 2008, The international journal of biochemistry & cell biology.

[5]  M. Pencina,et al.  Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. , 2007, JAMA.

[6]  E. Gambineri,et al.  Role of regulatory T cells and FOXP3 in human diseases. , 2007, The Journal of allergy and clinical immunology.

[7]  S. Money,et al.  Commentary on: Redgrave JNE, Lovett JK, Gallagher PJ, et al. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford Plaque Study. Circulation. 2006; 113:2320-2328. , 2007, Perspectives in vascular surgery and endovascular therapy.

[8]  G. Keren,et al.  Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. , 2006, European heart journal.

[9]  Vasilis Ntziachristos,et al.  Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo , 2006, Circulation.

[10]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[11]  K. Moore,et al.  Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells , 2006, Circulation.

[12]  P J Gallagher,et al.  Histological Assessment of 526 Symptomatic Carotid Plaques in Relation to the Nature and Timing of Ischemic Symptoms: The Oxford Plaque Study , 2006, Circulation.

[13]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[14]  R. Flavell,et al.  Natural regulatory T cells control the development of atherosclerosis in mice , 2006, Nature Medicine.

[15]  S. Hazen,et al.  Formation of dysfunctional high-density lipoprotein by myeloperoxidase. , 2005, Trends in cardiovascular medicine.

[16]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[17]  P. Barter,et al.  High-density lipoproteins as therapeutic targets , 2005, Current opinion in lipidology.

[18]  P. Barter,et al.  Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits , 2005, Circulation.

[19]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[20]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[21]  A. Chait,et al.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Kuis,et al.  CD4+CD25bright Regulatory T Cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis , 2004, The Journal of Immunology.

[23]  C. Ruiz,et al.  High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. , 2003, Journal of vascular surgery.

[24]  R Eugene Zierler,et al.  Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in Ultrasound Consensus Conference. , 2003, Radiology.

[25]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[26]  A H Davies,et al.  The symptomatic carotid plaque. , 2000, Stroke.

[27]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[28]  D. Sackett,et al.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. , 1998, The New England journal of medicine.

[29]  H. Steinmetz,et al.  Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. , 1998, Stroke.

[30]  A. Davies,et al.  Carotid plaque characteristics and presenting symptom , 1997, The British journal of surgery.

[31]  J. Toole.  ACAS recommendations for carotid endarterectomy , 1996, The Lancet.

[32]  J. Toole.  ACAS recommendations for carotid endarterectomy. ACAS Executive Committee. , 1996, Lancet.

[33]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[34]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.